TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

GENFIT annonce son calendrier financier pour 2026

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Genfit
GENFIT annonce son calendrier financier pour 2026

GENFIT, a clinical-stage biopharmaceutical company focused on rare liver diseases, announced its 2026 financial calendar with key publication dates for revenue, financial results, and shareholder meetings. The company continues development of its lead asset G1090N for acute-on-chronic liver failure with favorable Phase 1 safety data, and GNS561 showing promising antitumor activity in cholangiocarcinoma combination therapy.

Insights
BRK.A   positive

Purchased over 17.8 million Alphabet shares, indicating confidence in the tech company's future


IPSEY   neutral

Ipsen is mentioned as a major shareholder (8% stake since 2021) and commercializes Iqirvo® (elafibranor) in multiple countries. While this represents a commercial partnership, the article provides no specific updates on Ipsen's performance or commercial results, warranting a neutral stance.